What happens after stopping semaglutide? The STEP 1 extension explained
Withdrawal studies show that regain is common when treatment stops. That reflects chronic biology, not personal failure, and it is why maintenance planning starts early.
By Peptis Publication · 2026-08-21 · 5 minute read · Education only
What the withdrawal data showed
In the STEP 1 extension, one year after stopping semaglutide and lifestyle intervention, participants regained about two thirds of their prior weight loss, and many cardiometabolic improvements moved back toward baseline. In STEP 4, participants switched from semaglutide to placebo gained 6.9% of body weight from week 20 to week 68, while those who continued lost a further 7.9%.
How to read this honestly
This is not evidence that the medicine breaks metabolism. Obesity is a chronic, relapsing condition, and the biology defending body weight returns when treatment stops. Framing regain as a personal failure misreads the data and makes planning harder.
What early maintenance looks like
The practical consequence is that maintenance is not a phase that starts later. Habit formation, progressive strength work, workable protein structure and simple monitoring of weight trend, waist, training performance and everyday function are all more useful when they are established during treatment. Decisions about continuing, changing or stopping therapy belong with your current clinician.
What the evidence cannot tell us
- Withdrawal trials compare stopping with continuing; they do not test tapering strategies or individual plans.
- Group regain averages do not predict any single person’s outcome.
Sources
- Wilding et al., STEP 1 extension, Diabetes, Obesity and Metabolism, 2022, dossier [9]
- Rubino et al., STEP 4, JAMA, 2021, dossier [10]
Keep reading
Talk with your current clinician before changing medication, diet, supplements or exercise.